Belgium's Ajinomoto doubles Indian small-molecule manufacturing cap with new facility

Ajinomoto India site
Ajinomoto bought out a joint venture late last year for its Visakhapatnam, India small-molecule site. (Ajinomoto)

Belgian CDMO Ajinomoto Bio-Pharma Services has been on a run in recent of years expanding its operations around the world. That was the goal of an Indian joint venture buyout back in 2018—and now Ajinomoto is ready to double down on that earlier investment. 

Ajinomoto is building a 91,500-square-foot small molecule manufacturing facility at its existing Visakhapatnam, India, complex that will double the site's production capacity, the Belgian CDMO said Thursday. 

The small-molecule facility began construction in late July and is expected to go online in 2022, Ajinomoto said. 

Virtual Roundtable

ESMO Post Show: Highlights from the Virtual Conference

Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.

The CDMO's newest facility will help produce active pharmaceutical ingredients (APIs) and drug intermediates with a total of 310,000 liters of capacity. In addition, Ajinomoto has renovated its existing laboratory space to boost its R&D efforts. 

All told, the expansion and renovations are expected to add 60 new jobs at the facility, Ajinomoto said. 

“The increased manufacturing capacity at Aji Bio-Pharma India offers a significant advantage for our small molecule customers, who now have a variety of options to meet their manufacturing needs,” said Peter Stuyck, vice president and head of European operations.

RELATED: Ajinomoto Bio-Pharma buys Indian API plant from JV partner

Suggested Articles

Bristol-Myers already has one Opdivo combo approved in kidney cancer, but it’s going for another—and new trial data could be just the ticket.

Trodelvy's bladder cancer data look weaker compared with what Seattle Genetics' rival drug Padcev achieved in its own trial.

Merck’s Keytruda is battling Bristol Myers' Opdivo in adjuvant melanoma, and it just racked up trial results that will help it even the playing field.